| # | Title | Journal | Year | Citations |
|---|
| 1 | Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy | Thrombosis Research | 2020 | 1,690 |
| 2 | Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) | Intensive Care Medicine | 2020 | 1,536 |
| 3 | Sepsis and septic shock | Lancet, The | 2018 | 1,205 |
| 4 | Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours | Journal of Pathology | 2014 | 1,151 |
| 5 | Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation | JAMA - Journal of the American Medical Association | 2019 | 953 |
| 6 | The gut-liver axis in liver disease: Pathophysiological basis for therapy | Journal of Hepatology | 2020 | 935 |
| 7 | Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline | Endoscopy | 2017 | 831 |
| 8 | Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial | Lancet Oncology, The | 2016 | 818 |
| 9 | Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) | Critical Care Medicine | 2020 | 816 |
| 10 | Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial | Lancet, The | 2016 | 771 |
| 11 | ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment | Journal of Crohn's and Colitis | 2020 | 741 |
| 12 | COVID-19 pandemic: perspectives on an unfolding crisis | British Journal of Surgery | 2020 | 647 |
| 13 | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | Lancet, The | 2017 | 633 |
| 14 | COVID-19 vaccines: where we stand and challenges ahead | Cell Death and Differentiation | 2021 | 626 |
| 15 | Neutrophil diversity and plasticity in tumour progression and therapy | Nature Reviews Cancer | 2020 | 548 |
| 16 | Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study | Lancet Respiratory Medicine,the | 2020 | 516 |
| 17 | The interaction of anticancer therapies with tumor-associated macrophages | Journal of Experimental Medicine | 2015 | 507 |
| 18 | A guiding map for inflammation | Nature Immunology | 2017 | 506 |
| 19 | Macrophage heterogeneity in the context of rheumatoid arthritis | Nature Reviews Rheumatology | 2016 | 493 |
| 20 | ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment | Journal of Crohn's and Colitis | 2020 | 478 |
| 21 | Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock | JAMA - Journal of the American Medical Association | 2019 | 471 |
| 22 | Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement | Endoscopy | 2017 | 451 |
| 23 | The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity | Immunity | 2018 | 436 |
| 24 | Sexual Dimorphism in Innate Immunity | Clinical Reviews in Allergy and Immunology | 2019 | 430 |
| 25 | Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study | Lancet Haematology,the | 2020 | 430 |
| 26 | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial | Lancet Oncology, The | 2017 | 425 |
| 27 | Crohn’s disease | Nature Reviews Disease Primers | 2020 | 420 |
| 28 | Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy | Frontiers in Immunology | 2019 | 398 |
| 29 | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development | Journal of Hepatology | 2019 | 388 |
| 30 | Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial | Nature Medicine | 2021 | 353 |
| 31 | JAK–STAT pathway targeting for the treatment of inflammatory bowel disease | Nature Reviews Gastroenterology and Hepatology | 2020 | 336 |
| 32 | Application of Artificial Intelligence to Gastroenterology and Hepatology | Gastroenterology | 2020 | 335 |
| 33 | PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer | Cell | 2015 | 334 |
| 34 | ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy | Aging | 2020 | 331 |
| 35 | Development and validation of the Nancy histological index for UC | Gut | 2017 | 322 |
| 36 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 319 |
| 37 | Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis | Clinical Gastroenterology and Hepatology | 2016 | 303 |
| 38 | Interleukin-17 and innate immunity in infections and chronic inflammation | Journal of Autoimmunity | 2015 | 293 |
| 39 | IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy | Immunological Reviews | 2018 | 288 |
| 40 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | Lancet Oncology, The | 2018 | 285 |
| 41 | Complement in cancer: untangling an intricate relationship | Nature Reviews Immunology | 2018 | 279 |
| 42 | International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis | International Forum of Allergy and Rhinology | 2018 | 273 |
| 43 | Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma | Journal of Clinical Oncology | 2018 | 273 |
| 44 | EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) | European Journal of Nuclear Medicine and Molecular Imaging | 2019 | 265 |
| 45 | The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update | Journal of Crohn's and Colitis | 2021 | 265 |
| 46 | Hospital surge capacity in a tertiary emergency referral centre during the COVID‐19 outbreak in Italy | Anaesthesia | 2020 | 264 |
| 47 | Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta‐analysis of malignant transformation rate by subtype | Head and Neck | 2020 | 251 |
| 48 | Molecular therapies for HCC: Looking outside the box | Journal of Hepatology | 2020 | 250 |
| 49 | Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth | Nature Microbiology | 2020 | 248 |
| 50 | Diagnosis and management of NSAID‐Exacerbated Respiratory Disease (N‐ERD)—a EAACI position paper | Allergy: European Journal of Allergy and Clinical Immunology | 2019 | 247 |
